Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
Pfizer will invest €90.5 million in Valneva Planned Phase 3 study confirmed to initiate in Q3 2022 SAINT-HERBLAIN, France & NEW YORK–(BUSINESS WIRE)–Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Equity Subscription Agreement and have updated the terms of … [Read more…]
